ID: ALA2049156

Max Phase: Preclinical

Molecular Formula: C37H72N14O7

Molecular Weight: 825.07

Molecule Type: Protein

Associated Items:

Representations

Canonical SMILES:  CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C(C)C

Standard InChI:  InChI=1S/C37H72N14O7/c1-20(2)18-27(46-23(7)52)33(56)50-28(19-21(3)4)34(57)48-26(14-11-17-45-37(42)43)32(55)51-29(22(5)6)35(58)49-25(12-8-9-15-38)31(54)47-24(30(39)53)13-10-16-44-36(40)41/h20-22,24-29H,8-19,38H2,1-7H3,(H2,39,53)(H,46,52)(H,47,54)(H,48,57)(H,49,58)(H,50,56)(H,51,55)(H4,40,41,44)(H4,42,43,45)/t24-,25-,26-,27-,28-,29-/m0/s1

Standard InChI Key:  AAYRDVQZUZFTDJ-AQRCPPRCSA-N

Associated Targets(Human)

Furin 909 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Subtilisin/kexin type 6 163 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: ProteinTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 825.07Molecular Weight (Monoisotopic): 824.5708AlogP: -2.20#Rotatable Bonds: 29
Polar Surface Area: 367.51Molecular Species: BASEHBA: 10HBD: 14
#RO5 Violations: 2HBA (Lipinski): 21HBD (Lipinski): 18#RO5 Violations (Lipinski): 3
CX Acidic pKa: 11.81CX Basic pKa: 11.63CX LogP: -3.39CX LogD: -10.23
Aromatic Rings: 0Heavy Atoms: 58QED Weighted: 0.02Np Likeness Score: 0.15

References

1. López-Vallejo F, Martínez-Mayorga K..  (2012)  Furin inhibitors: importance of the positive formal charge and beyond.,  20  (14): [PMID:22682919] [10.1016/j.bmc.2012.05.029]
2. Levesque C, Fugère M, Kwiatkowska A, Couture F, Desjardins R, Routhier S, Moussette P, Prahl A, Lammek B, Appel JR, Houghten RA, D'Anjou F, Dory YL, Neugebauer W, Day R..  (2012)  The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells.,  55  (23): [PMID:23126600] [10.1021/jm3011178]

Source